Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1987 Sep;25(2):81–86. doi: 10.1007/BF00199945

Infiltration of primary and metastatic melanomas with macrophages of the 25F9-positive phenotype

Eva-Bettina Bröcker 1,✉, Gabriele Zwadlo 1, Ludwig Suter 3, Martin Brune 1, Clemens Sorg 1
PMCID: PMC11038079  PMID: 3664532

Abstract

In order to gain insight into the role of macrophages in human melanoma, we studied fresh-frozen material from 15 dysplastic nevi, 199 primary melanomas, 107 melanoma metastases, and paraffin sections from 98 primary melanomas with the monoclonal antibody 25F9 which recognizes an 86×103 dalton protein present on a subset of mature human macrophages. Considerable infiltration of tumors with 25F9-positive macrophages was observed in 2 dysplastic nevi (13%), 87 primary melanomas (44%), and 45 metastases (42%). The degree of intratumoral macrophage infiltration correlated with expression of class II HLA-DR antigens on tumor cells, in primary melanoma with a tumor thickness above 0.75 mm, and with the occurence of metastases within 2 years. In paraffin sections, intratumoral 25F9-positive macrophages also correlated with metastatic spread of primary tumors after longer follow-up. Metastases revealed a higher degree of macrophage infiltration following systemic or local immunotherapy, compared with untreated metastases, or metastases removed during chemotherapy. Of 38 patients who died within an observation period of 1 year, 19 (50%) had considerable infiltration of metastases with 25F9-positive macrophages, whereas this was found in only 4 of 12 patients (33%), who survived for longer than 2 years following metastases removal. A higher degree of 25F9-positive macrophages correlated with a shift towards the T8-positive subsets within the T cell compartment of the infiltrate. Our results suggest that accumulation of 25F9-positive macrophages in melanomas indicates more aggressive tumor properties.

Keywords: Melanoma, Metastatic Melanoma, Paraffin Section, Human Melanoma, Macrophage Infiltration

References

  • 1.Allen C, Hogg N. Monocytes and other infiltrating cells in human colorectal tumours identified by monoclonal antibodies. Immunology. 1985;55:289. [PMC free article] [PubMed] [Google Scholar]
  • 2.De Baetselier P, Kapon A, Katzav S, Tzehoval E, Dekegel D, Segal S, Feldman M. Selecting, accelerating and suppressing interactions between macrophages and tumor cells. Invasion Metastasis. 1985;5:106. [PubMed] [Google Scholar]
  • 3.Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;1:902. doi: 10.1097/00000658-197011000-00017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bröcker E-B, Suter L, Sorg C. HLA-DR antigen expression in primary melanomas of the skin. J Invest Dermatol. 1984;82:244. doi: 10.1111/1523-1747.ep12260181. [DOI] [PubMed] [Google Scholar]
  • 5.Bröcker E-B, Sorg C, Zwadlo G, Macher E. Inflammatory infiltrates in human tumors: the mononuclear cell infiltrates in malignant melanoma of the skin. In: Macher E, Sorg C, editors. Local immunity in cancer. Münster: R & B; 1986. p. 35. [Google Scholar]
  • 6.Carrel S, Schmidt-Kessen A, Giuffré L. Recombinant interferon-γ can induce the expression of HLA-DR and DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens. Eur J Immunol. 1985;15:118. doi: 10.1002/eji.1830150204. [DOI] [PubMed] [Google Scholar]
  • 7.Eccles SA, Alexander P. Macrophage content of tumours in relation to metastatic spread and host immune reaction. Nature. 1974;250:667. doi: 10.1038/250667a0. [DOI] [PubMed] [Google Scholar]
  • 8.Evans R. Host cells in transplanted murine tumors and their possible relevance to tumor growth. J Reticuloendothel Soc. 1979;26:427. [PubMed] [Google Scholar]
  • 9.Evans R, Duffy T, Cullen RT. Tumor-associated macrophages stimulate the proliferation of murine tumor cells surviving treatment with the oncolytic cyclophosphamide analogue Asta Z-7557: In vivo implications. In J Cancer. 1984;34:883. doi: 10.1002/ijc.2910340622. [DOI] [PubMed] [Google Scholar]
  • 10.Fidler IJ. The role of macrophages in tumor rejection. In: Macher E, Sorg C, editors. Local immunity in cancer. Münster: R & B; 1986. p. 38. [Google Scholar]
  • 11.Fogler WE, Fidler IJ. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages. Cancer Res. 1985;45:14. [PubMed] [Google Scholar]
  • 12.Gerdes J, Lemake H, Baisch H, Wacker H-H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710. [PubMed] [Google Scholar]
  • 13.Goodwin JS, Husby G, Williams RC., Jr Prostaglandin E and cancer growth. Cancer Immunol Immunother. 1980;8:3. [Google Scholar]
  • 14.Heidl G, Davaris P, Jagoda MS, Düchting S, Bierhoff E, Grüter Th, Zwadlo G, Grundmann E. Immunohistochemical investigation of the macrophage infiltrate in gastric carcinoma using the monoclonal antibody 25F9. Hematol Rev Commun. 1986;1:140. [Google Scholar]
  • 15.Hersey P, Murray E, Grace J, McCarthy WH. Current research on immunopathology of melanoma: Analysis of lymphocyte populations in relation to antigen expression and histological features of melanoma. Pathology. 1985;17:385. doi: 10.3109/00313028509105490. [DOI] [PubMed] [Google Scholar]
  • 16.Hibbs JB., Jr Activated macrophages as cytotoxic effector cells. I. Inhibition of specific and nonspecific tumor resistance by trypan blue. Transplantation. 1975;19:77. doi: 10.1097/00007890-197501000-00015. [DOI] [PubMed] [Google Scholar]
  • 17.Houghton AN, Thomson TM, Gross D, Oettgen HF, Old LJ. Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human γ-interferon. J Exp Med. 1984;160:255. doi: 10.1084/jem.160.1.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kalish R, Brody NI. The effects of tumor facilitating factor of B16 melanoma on the macrophage. J Invest Dermatol. 1983;80:162. doi: 10.1111/1523-1747.ep12533308. [DOI] [PubMed] [Google Scholar]
  • 19.Karavodin LM, Giuliano AE, Golub SH. T lymphocyte subsets in patients with malignant melanoma. Cancer Immunol Immunother. 1981;11:251. [Google Scholar]
  • 20.Knop J, Malorny U, Macher E. Selective induction of delayed hypersensitivity T-effector and T-suppressor lymphocytes in vitro by hapthenized bone marrow-derived macrophages. Cell Immunol. 1984;88:411. doi: 10.1016/0008-8749(84)90174-6. [DOI] [PubMed] [Google Scholar]
  • 21.Kornstein MJ, Brooks JSJ, Elder DE. Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi. Cancer Res. 1983;43:2749. [PubMed] [Google Scholar]
  • 22.Loveless SE, Heppner GH. Tumor-associated macrophages of mouse mammary tumors. I. Differential cytotoxicity of macrophages from metastatic and nonmetastatic tumors. J Immunol. 1983;131:2074. [PubMed] [Google Scholar]
  • 23.Lovett D, Kozan B, Hadam M, Resch K, Gemsa D. Macrophage cytotoxicity: Interleukin 1 as a mediator of tumor cytostasis. J Immunol. 1986;136:340. [PubMed] [Google Scholar]
  • 24.Mahoney KH, Fulton AM, Heppner GH. Tumor-associated macrophages of mouse mammary tumors. II. Differential distribution of macrophages from metastatic and nonmetastatic tumors. J Immunol. 1983;131:2079. [PubMed] [Google Scholar]
  • 25.Murray JL, Springle C, Ishmael DR, Lee ET, Longley R, Kollmorgen GM, Nordquist RL. Adherent indomethacin-sensitive suppressor cells in malignant melanoma. Cancer Immunol Immunother. 1981;11:165. [Google Scholar]
  • 26.Polverini PJ, Cotran RS, Gimbrone MA, Jr, Unanue ER. Activated macrophages induce vascular proliferation. Nature. 1977;269:804. doi: 10.1038/269804a0. [DOI] [PubMed] [Google Scholar]
  • 27.Poppema S, Bröcker E-B, De Leij L, Terbrack D, Visscher T, Ter Haar A, Macher E, Thé TH, Sorg C. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin. Clin Exp Immunol. 1983;51:77. [PMC free article] [PubMed] [Google Scholar]
  • 28.Ruiter DJ, Bhan AK, Harrist TJ, Sonber AJ, Mihm MC., Jr Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol. 1982;129:2808. [PubMed] [Google Scholar]
  • 29.Salmon SE, Hamburger AW. Immunoproliferation and cancer: a common macrophage-derived promoter substance. Lancet. 1978;I:1289. doi: 10.1016/s0140-6736(78)91270-9. [DOI] [PubMed] [Google Scholar]
  • 30.Sorg C, Bröcker E-B, Zwadlo G, Redmann K, Feige U, Ax W, Feller AC. A monoclonal antibody to a formalde-hyde-resistant epitope on the polymorphic constant region of the HLA-DR antigen. Transplantation. 1985;39:90. [PubMed] [Google Scholar]
  • 31.Suter L, Bröcker E-B, Brüggen J, Riter DJ, Sorg C. Heterogeneity of primary and metastatic human malignant melanoma as detected with monoclonal antibodies in cryostat sections of biopsies. Cacner Immunol Immunother. 1983;16:53. doi: 10.1007/BF00199906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Talmadge JE, Key M, Fidler IJ. Macrophage content of metastatic and nonmetastatic rodent neoplasms. J Immunol. 1981;126:2245. [PubMed] [Google Scholar]
  • 33.Zwadlo G, Feige U, von Bassewitz DB, Bröcker E-B, Sorg C. Monoclonal antibodies against human macrophages: distribution of macrophage subtypes in normal, inflammatory and tumor tissue. Immunobiology. 1983;165:385. [Google Scholar]
  • 34.Zwadlo G, Bröcker E-B, von Bassewitz DB, Feige U, Sorg C. A monoclonal antibody to a differentiation antigen present on mature macrophages and absent from monocytes. J Immunol. 1985;134:1487. [PubMed] [Google Scholar]
  • 35.Zwadlo G, Bröcker E-B, Sorg C, Czarnetzki C. Distribution of mononuclear phagocytes in urticarias. J Invest Dermatol. 1986;87:176. [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES